This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CEQUA | |
|---|---|
| Name | CEQUA |
| Tradename | CEQUA |
| Generic name | cyclosporine ophthalmic solution |
| Routes | Ophthalmic |
| Class | Calcineurin inhibitor |
| Atc prefix | S01 |
| Atc suffix | EE24 |
| Legal status | Prescription-only |
| Chemical formula | C62H111N11O12 |
CEQUA
CEQUA is a prescription ophthalmic formulation of cyclosporine marketed for treatment of certain ocular surface disorders. It is presented as a 0.09% cyclosporine aqueous nanomicellar solution designed to enhance corneal and conjunctival drug delivery relative to traditional oil-based ophthalmic suspensions. The product has been evaluated in clinical trials and regulatory submissions involving endpoints such as tear production, ocular surface staining, and patient-reported symptoms.
CEQUA is indicated primarily for the treatment of keratoconjunctivitis sicca associated with decreased tear production. Clinical development and labeling draw on outcome measures familiar from trials used in approval dossiers submitted to regulators such as the U.S. Food and Drug Administration, with efficacy assessments paralleling those used in studies of other ophthalmic anti-inflammatory agents. In practice, CEQUA is prescribed by ophthalmologists and optometrists managing patients with aqueous-deficient dry eye related to conditions recognized by specialists in Rheumatology, Ophthalmology, Immunology, and Endocrinology. It may be considered in the context of systemic conditions linked to ocular surface disease, including entities encountered by clinicians in Internal medicine and Rheumatology clinics.
The active ingredient is cyclosporine, a cyclic polypeptide originally isolated and characterized in the late 1970s and studied in transplantation medicine alongside agents evaluated at institutions such as Mayo Clinic and Johns Hopkins Hospital. Cyclosporine acts as a calcineurin inhibitor by binding to cyclophilin and inhibiting the phosphatase activity of calcineurin, thereby reducing T-cell activation; this mechanism is shared with systemic formulations used in transplantation managed by centers such as Cleveland Clinic and Massachusetts General Hospital. Topical ocular delivery targets local lymphocyte-mediated inflammation on the ocular surface, similar in immunomodulatory principle to therapies studied at academic centers like Harvard Medical School and Stanford University School of Medicine. The nanomicellar vehicle in CEQUA enhances solubilization and corneal penetration relative to earlier oil-based ophthalmic cyclosporine products developed in pharmaceutical programs at companies comparable to those of major firms like Novartis and Allergan.
The labeled regimen for CEQUA is typically one drop instilled into the affected eye(s) twice daily, morning and evening, a schedule aligned with dosing paradigms used in pivotal trials overseen by clinical research sites affiliated with universities such as University of California, San Francisco and Columbia University. Prior to instillation, users are advised to follow instructions from prescribing clinicians at institutions including Bascom Palmer Eye Institute or Wills Eye Hospital regarding contact lens use and concomitant topical therapies. Administration considerations mirror guidance used for other ophthalmic agents evaluated in cooperative groups and trial networks like American Academy of Ophthalmology clinical research initiatives.
CEQUA is contraindicated in individuals with known hypersensitivity to cyclosporine or any component of the formulation, consistent with safety principles applied by regulatory bodies including European Medicines Agency and U.S. Food and Drug Administration. Caution is advised when prescribing to patients with active ocular infections encountered in specialty clinics such as Scheie Eye Institute and tertiary centers like Moorfields Eye Hospital, because immunomodulatory effects could theoretically affect local host defenses. Clinicians often weigh risks in patients with systemic immunosuppression managed by teams at institutions like MD Anderson Cancer Center or Stanford Cancer Institute and coordinate care accordingly.
Reported local adverse effects in clinical studies include transient ocular burning, stinging, and hyperemia, analogous to tolerability profiles observed in trials of other topical immunomodulators conducted at research centers such as University of Michigan Kellogg Eye Center and Duke University Eye Center. Less common findings documented during postmarketing surveillance and clinical programs overseen by surveillance systems affiliated with agencies like Centers for Disease Control and Prevention and national pharmacovigilance centers include ocular pain and visual disturbance; systemic adverse events are uncommon given minimal systemic absorption documented in pharmacokinetic studies performed by academic pharmacology groups at universities such as University of Pennsylvania.
The active moiety, cyclosporine A, is a cyclic undecapeptide with a molecular formula often cited in chemical literature curated by repositories like PubChem and chemical suppliers used by research laboratories at California Institute of Technology. CEQUA employs a nanomicellar aqueous delivery system developed to improve solubilization and ocular bioavailability compared with conventional oil-based formulations originally commercialized following translational research at institutions such as University of Basel and pharmaceutical innovators linked to Sandoz. Excipients and manufacturing processes adhere to quality standards promulgated by regulatory authorities including International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidance and Good Manufacturing Practice frameworks applied in facilities inspected by agencies like U.S. Food and Drug Administration.
CEQUA received regulatory approval following submission of clinical and manufacturing data to agencies such as the U.S. Food and Drug Administration and has been marketed subject to prescription-only status in jurisdictions following review pathways used by regulators like the European Medicines Agency for ophthalmic products. Approval decisions referenced pivotal trials and labeling comparable to decisions for other ophthalmic immunomodulators reviewed by advisory committees convened by bodies including the National Institutes of Health and professional associations such as the American Academy of Ophthalmology. Postapproval surveillance and pharmacovigilance activities continue under frameworks operated by national agencies like the U.S. Food and Drug Administration and regional regulators across Europe and Asia.
Category:Ophthalmology drugs